Dr. Jenifer Siegelman conducts interdisciplinary research at Worcester Polytechnic Institute on system dynamics and the modeling of healthcare system behavior, working with Professor Michael Radzicki's research group. Her interests focus on how interactions among patients, clinicians, healthcare organizations, technologies, incentives, and policy produce system-level behaviors and outcomes. Her work draws on her experience as a physician, practice leader, clinical researcher, pharmaceutical executive, and healthcare technology leader.
Before joining WPI, Dr. Siegelman held leadership positions at Takeda Pharmaceuticals spanning clinical development, translational medicine, oncology, gastroenterology, immunology, and emerging technologies. Most recently, she served as Head of Late Translational Oncology and previously founded and led Takeda's Novel and Emerging Technologies group. Her work included clinical development strategy, quantitative imaging, digital and pharmacodynamic biomarkers, innovative clinical trial design, and the application of artificial intelligence and other emerging technologies to drug development. She also led a Takeda–MIT artificial intelligence collaboration.
Earlier at Takeda, she was Senior Medical Director in the Cell Therapy Engine and a medical and translational leader for gastroenterology programs. In these roles, she worked at the intersection of clinical medicine, drug development, technology, and quantitative measurement, contributing to programs from first-in-human studies through later-stage development and regulatory activities.
Before entering the pharmaceutical industry, Dr. Siegelman practiced clinical radiology and held academic and healthcare leadership positions at Brigham and Women's Hospital/Harvard Medical School, the NIH Clinical Center, Norwich Diagnostic Imaging, and Yale School of Medicine. At Brigham and Women's, she was an attending radiologist, Quality Officer, and principal investigator in imaging and biomarker research. As Managing Partner and Medical Director of CT and Abdominal Imaging at Norwich Diagnostic Imaging, she developed advanced imaging programs, chaired multidisciplinary clinical conferences, and led a system-wide radiation stewardship initiative.
More recently, she served as fractional Chief Medical Officer of a healthcare AI company focused on evaluating the safety, performance, and governance of AI-based medical systems. Her research increasingly centers on healthcare as a complex adaptive system and on using system dynamics to understand unintended consequences, feedback relationships, adoption of innovation, and resource allocation, which are difficult to evaluate with conventional linear approaches.
Dr. Siegelman has published in gastroenterology, quantitative imaging, imaging informatics, and artificial intelligence. She holds several patents and has served as a scientific reviewer for the NIH and FDA, has contributed to the RSNA Quantitative Imaging Biomarkers Alliance, and serves on the Scientific Advisory Board of WPI PracticePoint.
Education
- SUNY Downstate College of Medicine, MD (Alpha Omega Alpha)
- Johns Hopkins Hospital, Residency in Diagnostic Radiology
- Johns Hopkins Hospital, Fellowship in Abdominal/Body Imaging
- Johns Hopkins Bloomberg School of Public Health, MPH
- Johns Hopkins University, Kreiger School of Arts and Sciences, BA, Molecular Biology